---
title: "Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299313338.md"
description: "CNBC's 'Final Trades' featured picks from several analysts: Jenny Van Leeuwen Harrington selected Charles Schwab (SCHW), Jim Lebenthal chose Cleveland-Cliffs (CLF), Stephen Weiss named UnitedHealth Group (UNH), and Joseph Terranova picked Incyte (INCY). The segment also highlighted upcoming earnings for UnitedHealth. On Wednesday, shares posted mixed moves: CLF rose 3.1%, INCY gained 2.5%, while SCHW fell 2.4% and UNH slipped 0.2%."
datetime: "2026-09-17T11:31:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299313338.md)
  - [en](https://longbridge.com/en/news/299313338.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299313338.md)
generator: "portal-rs"
---

# Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” **Jenny Van Leeuwen Harrington**, chief executive officer of Gilman Hill Asset Management, LLC, picked **The Charles Schwab Corporation** (NYSE:SCHW).

Compass Point analyst Ed Engel, on Aug. 3, initiated coverage on Charles Schwab with a Buy rating and announced a price target of $135.

**Jim Lebenthal**, partner and chief market strategist at Cerity Partners, recommended **Cleveland-Cliffs Inc.** (NYSE:CLF), which recorded gains on Wednesday.

JP Morgan analyst Bennett Moore, on Sept. 9, maintained a Neutral rating on Cleveland-Cliffs and raised the price target from $11 to $13.

*Don’t forget to check out our premarket coverage here* 

**Stephen Weiss**, chief investment officer and managing partner of Short Hills Capital Partners, named **UnitedHealth Group Incorporated** (NYSE:UNH) as his final trade.

UnitedHealth Group said it will release its third-quarter financial results on Tuesday, Oct. 13, before the opening bell. Analysts expect the company to report quarterly earnings at $4.14 per share on revenue of $111.49 billion.

**Joseph M. Terranova**, senior managing director for Virtus Investment Partners, picked **Incyte Corporation** (NASDAQ:INCY).

Supporting his view, Canaccord Genuity analyst John Newman, on Aug. 20, initiated coverage on Incyte with a Buy rating and announced a price target of $152.

## **Price Action**

-   Charles Schwab shares fell 2.4% to close at $105.16 on Wednesday.
-   Cleveland-Cliffs shares gained 3.1% to close at $12.15 during the session.
-   UnitedHealth shares slipped 0.2% to settle at $375.26 on Wednesday.
-   Incyte shares gained 2.5% to $124.75 during the session.

 **See More: Top Value Stocks** 

*Photo via Shutterstock*

### Related Stocks

- [SCHW.US](https://longbridge.com/en/quote/SCHW.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [UNH.US](https://longbridge.com/en/quote/UNH.US.md)
- [CLF.US](https://longbridge.com/en/quote/CLF.US.md)
- [UNHG.US](https://longbridge.com/en/quote/UNHG.US.md)
- [UNHU.US](https://longbridge.com/en/quote/UNHU.US.md)
- [UNHW.US](https://longbridge.com/en/quote/UNHW.US.md)
- [SCHW-D.US](https://longbridge.com/en/quote/SCHW-D.US.md)
- [SCHW-J.US](https://longbridge.com/en/quote/SCHW-J.US.md)

## Related News & Research

- [Charles Schwab Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts](https://longbridge.com/en/news/300919589.md)
- [What Charles Schwab (SCHW)'s AI Client Assistant Means For Shareholders](https://longbridge.com/en/news/300654691.md)
- [Texas AG Targets UnitedHealth: Probe Examines Alleged Bribes, Care Delays and Coverage Denials](https://longbridge.com/en/news/301067031.md)
- [Learn Why The Bull Case For Incyte (INCY) Could Change Following Rare Disease Drug Approval](https://longbridge.com/en/news/300531594.md)
- [Cleveland-Cliffs upgraded at Wells Fargo on steel pricing power](https://longbridge.com/en/news/301067595.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**